Eloralintide

What Is Eloralintide?

Eloralintide, also known by its development code LY3841136, is a synthetic peptide designed to selectively activate the amylin 1 receptor (AMY1R). Amylin is a hormone released from the pancreas alongside insulin that plays a role in signaling fullness after eating, the same broad hormone family that Cagrilintide targets, though Eloralintide's design is specifically engineered for high selectivity toward the AMY1R subtype.

Unlike GLP-1-based medications, which act on a different receptor system tied to insulin and gut hormone signaling, Eloralintide works entirely through the amylin pathway. This distinct mechanism is part of why Eli Lilly has positioned it as a potential option for patients who don't tolerate GLP-1-based medications well, and it's also being studied in combination with incretin-based drugs like tirzepatide.

What Eloralintide is Being Researched For?

• Body Weight in Obesity

  A Phase 2 trial in 263 adults with obesity or overweight found that all tested doses of Eloralintide met the trial's primary endpoint, with mean weight reductions ranging from 9.5% to 20.1% at 48 weeks compared to 0.4% with placebo.^[1]

• Cardiometabolic Risk Factors

  The same trial found Eloralintide was associated with improvements across several cardiometabolic measures beyond weight alone, including waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation.^[1]

• Combination Research With Incretin Therapies

  Because Eloralintide works through a mechanism distinct from GLP-1 and GIP receptor agonists, Eli Lilly is separately evaluating it in combination with tirzepatide, exploring whether pairing an amylin-selective compound with incretin-based therapy produces effects beyond either approach alone.

How Eloralintide Works

• Selectively Activating the Amylin 1 Receptor

  Research points to Eloralintide activating AMY1R roughly 12 times more potently than the calcitonin receptor, a selectivity profile that distinguishes it from earlier, less-targeted amylin analogs and is part of its proposed favorable tolerability.^[1]

• Reducing Food Intake Through Satiety Signaling

  Research points to Eloralintide's effects being mediated primarily through satiety, the feeling of fullness, rather than the appetite-suppression pathways used by GLP-1 medications, which is the core distinction behind its different mechanism.^[1]

• A Favorable Tolerability Profile in Early Trials

  Research points to Eloralintide's Phase 2 trial reporting mild to moderate gastrointestinal symptoms and fatigue as the most common side effects, occurring more frequently at higher doses, with researchers specifically highlighting its tolerability profile as a notable trial finding.^[1]

Reconstitution and Handling

Because Eloralintide is not yet an approved medication, it's currently only available through clinical trials or as a research-grade compound sold as lyophilized powder, which requires reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Keel Bio's calculator is a commonly used tool for this. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Eloralintide's defining feature is its selective activation of the amylin 1 receptor, a mechanism distinct from the GLP-1 and GIP pathways used by semaglutide, tirzepatide, and retatrutide. Its Phase 2 results, published in late 2025, reported weight reductions competitive with the strongest incretin-based medications alongside a favorable tolerability profile, prompting rapid advancement into Phase 3 trials. It remains investigational, with combination research alongside tirzepatide an active area to watch.

Frequently Asked Questions

Sources and Research

1. Billings LK, et al. Eloralintide, a selective amylin receptor agonist, in adults with obesity or overweight: a randomised, phase 2 trial. Lancet. 2025.